|
US5612034A
(en)
*
|
1990-10-03 |
1997-03-18 |
Redcell, Inc. |
Super-globuling for in vivo extended lifetimes
|
|
CA2184002A1
(en)
*
|
1994-02-23 |
1995-08-31 |
Jeffrey M. Blaney |
Method and compositions for increasing the serum half-life of pharmacologically active agents
|
|
FR2726471B1
(fr)
|
1994-11-07 |
1997-01-31 |
Pf Medicament |
Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
|
|
EP0851767A1
(de)
*
|
1995-09-21 |
1998-07-08 |
Quadrant Healthcare (UK) Limited |
Vehikel und verstärker zur transzytose-wirkstoffabgabe
|
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
|
US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
|
AU721129B2
(en)
*
|
1996-01-08 |
2000-06-22 |
Genentech Inc. |
WSX receptor and ligands
|
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
|
US6372712B1
(en)
|
1998-05-22 |
2002-04-16 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
|
|
US20030190740A1
(en)
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
|
JP2002534059A
(ja)
|
1998-10-13 |
2002-10-15 |
ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド |
安定化された生物活性ペプチドおよび同定、合成および使用方法
|
|
AU2043901A
(en)
*
|
1999-11-19 |
2001-05-30 |
Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules having modulated pharmacokinetic properties and therapies based thereon
|
|
AU2044001A
(en)
|
1999-11-19 |
2001-05-30 |
Board Of Trustees Of The Leland Stanford Junior University |
Targeted bifunctional molecules and therapies based thereon
|
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
|
US6887842B1
(en)
|
1999-11-19 |
2005-05-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
|
|
EP1757311B1
(de)
*
|
1999-12-24 |
2009-02-11 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
|
|
US7608681B2
(en)
*
|
1999-12-24 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US7211395B2
(en)
|
2001-03-09 |
2007-05-01 |
Dyax Corp. |
Serum albumin binding moieties
|
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
|
JP2005521733A
(ja)
|
2002-03-26 |
2005-07-21 |
ダイアックス、コープ |
フィブリノーゲン結合部分
|
|
EP1837031B1
(de)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Methoden und Kompositionen um Diabetes zu behandeln
|
|
CN1678634A
(zh)
*
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
NZ540194A
(en)
|
2002-11-08 |
2008-07-31 |
Ablynx Nv |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US8642743B2
(en)
*
|
2004-04-06 |
2014-02-04 |
Affibody Ab |
Method for reducing the immune response to a biologically active protein
|
|
US8921528B2
(en)
*
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
CA2583137A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Therapeutic agents with decreased toxicity
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
MX2007006593A
(es)
*
|
2004-12-02 |
2008-03-04 |
Domantis Ltd |
Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
|
|
CA2589802A1
(en)
*
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Plad domain peptides with increased serum half life due to conjugation to domain antibodies
|
|
JP5185624B2
(ja)
|
2004-12-02 |
2013-04-17 |
ドマンティス リミテッド |
血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
|
|
AU2006249144B2
(en)
|
2005-05-18 |
2011-11-17 |
Ablynx Nv |
Improved NanobodiesTM against Tumor Necrosis Factor-alpha
|
|
EP1940880A2
(de)
*
|
2005-10-14 |
2008-07-09 |
Novo Nordisk A/S |
Behandeln von diabetes durch verwenden von il-1-hemmern
|
|
US20100129368A9
(en)
*
|
2006-10-11 |
2010-05-27 |
Ablynx N.V. |
Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
|
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
|
US9156914B2
(en)
|
2006-12-19 |
2015-10-13 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
DE08786222T1
(de)
|
2007-07-31 |
2010-11-25 |
Affibody Ab |
Neue albuminbindende zusammensetzungen, verfahren und anwendungen
|
|
EP2535350B1
(de)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Antikörperfusionen mit Doppelspezifität
|
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
US9187535B2
(en)
|
2007-12-19 |
2015-11-17 |
Affibody Ab |
Polypeptide derived from protein A and able to bind PDGF
|
|
ES2373832T3
(es)
|
2007-12-19 |
2012-02-09 |
Affibody Ab |
Polipéptido derivado de proteína a y capaz de unirse a pdgf.
|
|
EP2077272A1
(de)
|
2007-12-21 |
2009-07-08 |
Affibody AB |
Polypeptid-Bibliothek mit vorbestimmtem Gerüst
|
|
EP2072525A1
(de)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
Neue Polypeptide mit Bindungsaffinität für HER2
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
US9212226B2
(en)
|
2008-05-16 |
2015-12-15 |
Ablynx N.V. |
Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
|
|
LT2285408T
(lt)
|
2008-06-05 |
2019-01-25 |
Ablynx N.V. |
Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
|
|
US10407513B2
(en)
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
|
CN105646643A
(zh)
|
2008-10-29 |
2016-06-08 |
阿布林克斯公司 |
单域抗原结合性分子的纯化方法
|
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
CA2747644C
(en)
|
2008-12-19 |
2023-01-24 |
Ablynx N.V. |
Method for generation of immunoglobulin sequences
|
|
US20120165650A1
(en)
|
2010-12-22 |
2012-06-28 |
General Electric Company |
Her2 binders
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
CA2759942A1
(en)
|
2009-04-27 |
2010-10-07 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
|
|
ES2655877T3
(es)
|
2009-04-27 |
2018-02-22 |
Novartis Ag |
Composiciones y métodos para aumentar el crecimiento muscular
|
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
EP2496598B1
(de)
|
2009-11-04 |
2017-08-02 |
Affibody AB |
Her3-bindende polypeptide
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
HRP20251657T1
(hr)
|
2009-12-14 |
2026-02-13 |
Ablynx N.V. |
Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
|
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
EP2552962B1
(de)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
|
|
PH12012502018A1
(en)
*
|
2010-04-30 |
2018-03-21 |
Sanwa Kagaku Kenkyusho Co |
Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
|
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
|
BR112013000452A2
(pt)
|
2010-07-09 |
2020-02-11 |
Affibody Ab |
Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
|
|
BR112013007442A2
(pt)
|
2010-09-28 |
2019-09-24 |
Amylin Pharmaceuticals Llc |
polipeptídeos construídos tendo duração de ação realçada
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
EP2625203A1
(de)
|
2010-10-05 |
2013-08-14 |
Novartis AG |
Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
|
|
PY1147875A
(es)
|
2010-11-08 |
2015-08-03 |
Novartis Ag |
Polipéptidos de enlace de los receptores de quimiocina
|
|
EP3514169B1
(de)
|
2010-11-26 |
2024-03-06 |
Molecular Partners AG |
Repeat-protein, die sich an serumalbumin binden
|
|
US20140088019A1
(en)
|
2011-02-11 |
2014-03-27 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
|
AU2012234284B2
(en)
|
2011-03-28 |
2015-10-08 |
Ablynx Nv |
Bispecific anti-CXCR7 immunoglobulin single variable domains
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
NO2707391T3
(de)
|
2011-05-13 |
2018-04-07 |
|
|
|
US9505840B2
(en)
|
2011-05-27 |
2016-11-29 |
Ablynx N.V. |
Inhibition of bone resorption with RANKL binding peptides
|
|
MX2013014789A
(es)
|
2011-06-16 |
2014-01-20 |
Novartis Ag |
Proteinas solubles para utilizarse como productos terapeuticos.
|
|
AU2012273955A1
(en)
|
2011-06-22 |
2014-01-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
|
WO2012175691A1
(en)
|
2011-06-22 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
|
JP6472999B2
(ja)
|
2011-07-01 |
2019-02-20 |
ノバルティス アーゲー |
代謝障害を治療するための方法
|
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
|
AU2012310328A1
(en)
|
2011-09-23 |
2014-04-10 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. |
Anti-Tumor Necrosis Factor-alpha agents and uses thereof
|
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
|
CN106046161B
(zh)
|
2011-09-30 |
2019-09-13 |
埃博灵克斯股份有限公司 |
与C-Met相关的生物物质
|
|
JP6411214B2
(ja)
|
2011-11-11 |
2018-10-24 |
ユーシービー バイオファルマ エスピーアールエル |
アルブミン結合抗体及びその結合断片
|
|
KR102149028B1
(ko)
|
2012-02-20 |
2020-08-27 |
스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) |
인간 보체 c5에 결합하는 폴리펩티드
|
|
JP2015512902A
(ja)
*
|
2012-03-28 |
2015-04-30 |
アフィボディ・アーベー |
経口投与
|
|
JP2020033372A
(ja)
*
|
2012-03-28 |
2020-03-05 |
アフィボディ・アーベー |
経口投与
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
MX349035B
(es)
|
2012-05-17 |
2017-07-07 |
Extend Biosciences Inc |
Portadores para el suministro mejorado de farmaco.
|
|
US10155792B2
(en)
|
2012-09-25 |
2018-12-18 |
Affibody Ab |
Albumin binding polypeptide
|
|
WO2014053586A1
(en)
|
2012-10-05 |
2014-04-10 |
Affibody Ab |
Her3 binding polypeptides
|
|
PL2912054T3
(pl)
|
2012-10-25 |
2017-11-30 |
Affibody Ab |
Polipeptyd wiążący albuminę
|
|
JP6396303B2
(ja)
|
2012-10-25 |
2018-09-26 |
アフィボディ・アーベー |
アルブミン結合を含有するタンパク質の分離方法
|
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
|
EP2752426A1
(de)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Humane Serumalbumin bindende Verbindungen und Fusionsproteine daraus
|
|
LT2953969T
(lt)
|
2013-02-08 |
2019-12-10 |
Novartis Ag |
Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
|
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
|
EP3013370A1
(de)
|
2013-06-24 |
2016-05-04 |
Riogin Corporation |
Doppelbindungskonstrukte
|
|
WO2015022658A2
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
|
WO2015028558A1
(en)
|
2013-08-28 |
2015-03-05 |
Swedish Orphan Biovitrum Ab (Publ) |
Stable polypeptides binding to human complement c5
|
|
US9982022B2
(en)
|
2013-08-28 |
2018-05-29 |
Affibody Ab |
Binding polypeptides having a mutated scaffold
|
|
WO2015067986A1
(en)
|
2013-11-07 |
2015-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neuregulin allosteric anti-her3 antibody
|
|
WO2015091957A1
(en)
|
2013-12-20 |
2015-06-25 |
Affibody Ab |
Engineered albumin binding polypeptide
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
EP3161001A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
|
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
|
US9585934B2
(en)
|
2014-10-22 |
2017-03-07 |
Extend Biosciences, Inc. |
Therapeutic vitamin D conjugates
|
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
|
CA2969307A1
(en)
*
|
2014-12-04 |
2016-06-09 |
Novartis Ag |
Methods and compositions using klotho variant polypeptides
|
|
HK1245662A1
(zh)
|
2014-12-19 |
2018-08-31 |
Alexion Pharmaceuticals, Inc. |
治疗组织钙化的方法
|
|
US9458211B1
(en)
|
2015-04-02 |
2016-10-04 |
Molecular Partners Ag |
Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
|
|
ES3029413T3
(en)
|
2015-04-02 |
2025-06-24 |
Ablynx Nv |
Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
|
|
ES2984656T3
(es)
|
2015-05-13 |
2024-10-30 |
Ablynx Nv |
Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
|
|
HRP20191800T1
(hr)
|
2015-05-13 |
2019-12-27 |
Ablynx N.V. |
Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
|
|
WO2016188911A1
(en)
|
2015-05-22 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
|
EP3303380B1
(de)
|
2015-06-02 |
2020-01-15 |
Novo Nordisk A/S |
Insuline mit polaren rekombinanten erweiterungen
|
|
US10940204B2
(en)
|
2015-07-31 |
2021-03-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
|
WO2017055582A1
(en)
|
2015-10-01 |
2017-04-06 |
Novo Nordisk A/S |
Protein conjugates
|
|
EP3365027B1
(de)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
|
|
EP3368571B1
(de)
|
2015-10-30 |
2022-12-07 |
The Regents of The University of California |
Auf transformierenden wachstumsfaktor-beta ansprechende polypeptide und verfahren zu deren verwendung
|
|
CA3006398A1
(en)
|
2015-11-27 |
2017-06-01 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
|
EP3471747A1
(de)
|
2016-06-16 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von myointimaler proliferation
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
EP3491022B1
(de)
|
2016-07-29 |
2025-09-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
CA3039136A1
(en)
|
2016-09-02 |
2018-03-08 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
MY196882A
(en)
|
2016-09-22 |
2023-05-08 |
Molecular Partners Ag |
Recombinant binding proteins and their use
|
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
EP3565589A1
(de)
|
2017-01-04 |
2019-11-13 |
Research Institute at Nationwide Children's Hospital |
Dnabii-impfstoffe und antikörper mit erhöhter aktivität
|
|
AU2018206560B9
(en)
|
2017-01-04 |
2025-04-03 |
Research Institute At Nationwide Children's Hospital |
Antibody fragments for the treatment of biofilm-related disorders
|
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
|
EP3595445B1
(de)
|
2017-03-15 |
2024-09-04 |
The Research Institute at Nationwide Children's Hospital |
Zusammensetzung und verfahren zur brechung bakterieller biofilme ohne begleitentzündung
|
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー/エス |
オリゴマー伸長インスリン−Fcコンジュゲート
|
|
CN110997001A
(zh)
|
2017-06-02 |
2020-04-10 |
默克专利股份有限公司 |
Mmp13结合免疫球蛋白
|
|
US11261260B2
(en)
|
2017-06-02 |
2022-03-01 |
Merck Patent Gmbh |
ADAMTS binding immunoglobulins
|
|
IL270951B2
(en)
|
2017-06-02 |
2025-05-01 |
Merck Patent Gmbh |
ADAMTS5, MMP13 and aggrecan-binding polypeptides
|
|
CN118085076A
(zh)
|
2017-06-02 |
2024-05-28 |
埃博灵克斯股份有限公司 |
结合聚集蛋白聚糖的免疫球蛋白
|
|
EP3645564A1
(de)
|
2017-06-28 |
2020-05-06 |
Novartis AG |
Verfahren zur prävention und behandlung von harninkontinenz
|
|
IL307197B2
(en)
|
2017-07-11 |
2026-03-01 |
Alexion Pharma Inc |
Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
|
|
US12134790B2
(en)
|
2017-09-27 |
2024-11-05 |
Inozyme Pharma, Inc. |
Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
|
|
EP3470426A1
(de)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispezifischer antikörper
|
|
US12202911B2
(en)
|
2017-10-10 |
2025-01-21 |
Numab Therapeutics AG |
Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
|
|
EP3552631A1
(de)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CA3102036A1
(en)
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
US20210139610A1
(en)
|
2018-06-29 |
2021-05-13 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for mediating eps
|
|
PL3830119T3
(pl)
|
2018-08-01 |
2026-05-25 |
Imcheck Therapeutics |
Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych
|
|
WO2020053122A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
CN112771074A
(zh)
|
2018-10-05 |
2021-05-07 |
国家儿童医院研究所 |
用于酶促破坏细菌生物膜的组合物和方法
|
|
EP3947446A1
(de)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
KR20220016944A
(ko)
|
2019-06-04 |
2022-02-10 |
몰리큘라 파트너스 아게 |
개선된 안정성을 갖는 설계된 안키린 반복 도메인
|
|
PH12021553101A1
(en)
|
2019-06-12 |
2023-10-02 |
Novartis Ag |
Natriuretic peptide receptor 1 antibodies and methods of use
|
|
CA3145385A1
(en)
|
2019-07-08 |
2021-01-14 |
Steven D. Goodman |
Antibody compositions for disrupting biofilms
|
|
EP3785726A1
(de)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Faktor-viii-protein mit erhöhter halbwertszeit
|
|
AU2020342349A1
(en)
|
2019-09-02 |
2022-03-03 |
Biotest Ag |
Factor VIII protein with increased half-life
|
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
|
US12441788B2
(en)
|
2019-09-27 |
2025-10-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
|
US20210147525A1
(en)
|
2019-10-18 |
2021-05-20 |
The Regents Of The University Of California |
Methods and compositions for treating pathogenic blood vessel disorders
|
|
EP3816185A1
(de)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispezifischer antikörper gegen pd-l1 und ein tumorassoziiertes antigen
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
EP4072682A1
(de)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper mit spezifität gegen her4 und verwendungen davon
|
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
|
EP4087863A1
(de)
|
2020-01-10 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Rspo1-proteine und ihre verwendung
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
|
EP3915580A1
(de)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispezifischer antikörper
|
|
WO2022002880A1
(en)
|
2020-06-29 |
2022-01-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-protein s single-domain antibodies and polypeptides comprising thereof
|
|
EP3988568A1
(de)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Kombinationsbehandlung
|
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
|
WO2022098745A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, delivery systems, and methods useful in tumor therapy
|
|
EP4251187A4
(de)
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
Tumorspezifische spaltbare linker
|
|
US20240067758A1
(en)
|
2020-12-07 |
2024-02-29 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
EP4259661A1
(de)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
|
|
JP7858665B2
(ja)
|
2021-02-02 |
2026-05-14 |
ヌマブ セラピューティックス アーゲー |
Ror1およびcd3に対する特異性を有する多重特異性抗体
|
|
WO2022171892A1
(en)
|
2021-02-15 |
2022-08-18 |
Affibody Ab |
New her2-binding polypeptide
|
|
EP4294834A2
(de)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Einzeldomänenantikörper zur neutralisierung von sars-cov-2
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
EP4183800A1
(de)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Neue sars-cov-2-neutralisierende antikörper
|
|
JP2025510997A
(ja)
|
2022-03-30 |
2025-04-15 |
ノバルティス アーゲー |
抗ナトリウム利尿ペプチド受容体1(npr1)抗体を使用して障害を治療する方法
|
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
|
EP4584291A1
(de)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antikörper mit spezifität gegen ltbp2 und verwendungen davon
|
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
|
US12233115B2
(en)
|
2022-09-30 |
2025-02-25 |
Extend Biosciences, Inc. |
Long-acting parathyroid hormone
|
|
JP2025532758A
(ja)
|
2022-10-04 |
2025-10-03 |
イムチェック セラピューティクス エスエーエス |
癌の治療における使用のためのbtn3a活性化抗体、bcl2阻害剤及び低メチル化剤の併用
|
|
US20260103529A1
(en)
|
2022-10-18 |
2026-04-16 |
Confo Therapeutics N.V. |
Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
|
|
JP2026506893A
(ja)
|
2023-02-23 |
2026-02-27 |
イムチェック セラピューティクス エスエーエス |
Btn3a活性化抗体と免役チェックポイント阻害剤の併用
|
|
AU2024245676A1
(en)
|
2023-03-30 |
2025-10-09 |
272BIO Limited |
Gnrh-binding polypeptides and uses thereof
|
|
WO2024236156A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
EP4477236A1
(de)
|
2023-06-14 |
2024-12-18 |
Inatherys |
Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
WO2025158010A1
(en)
|
2024-01-25 |
2025-07-31 |
Affibody Ab |
Her2-binding polypeptide
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025242732A1
(en)
|
2024-05-21 |
2025-11-27 |
Institut National de la Santé et de la Recherche Médicale |
Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|